Affiliation:
1. Central Georgia Hematology and Oncology Associates, Macon, Georgia, USA
Abstract
Abstract
Nausea and vomiting are two of the most feared side effects of cancer chemotherapy and radiotherapy. Chemotherapy-induced nausea and vomiting can be broadly categorized as acute (occurring within 24 hours of therapy), delayed (persisting for 6–7 days after therapy), or anticipatory (occurring prior to chemotherapy administration). Breakthrough and refractory nausea and vomiting describe the symptoms of uncontrolled emesis. Evidence suggests that good control of nausea and vomiting during the acute period correlates with the control of delayed emesis. Conversely, protection failure during the first 24 hours has a high predictive value for delayed emesis in the same cycle.
The 5-HT3-receptor antagonists, regarded as the ‘gold standard’ in antiemetic therapy, are the first-line treatment for moderately and highly emetogenic chemotherapy and radiotherapy regimens in adults and children. Evidence suggests that the 5-HT3-receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.
Antiemetic therapeutic guidelines stress that the goal of therapy is to prevent cytostatic-induced nausea and vomiting. Therefore, the prophylactic use of the most effective antiemetic regimen—taking into consideration the emetogenicity of the chemotherapy and individual patient characteristics—must be adhered to in order to prevent acute, delayed, and anticipatory nausea and vomiting.
Publisher
Oxford University Press (OUP)
Reference81 articles.
1. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting;Hesketh;Cancer Invest,2000
2. On the receiving end—patient perception of the side-effects of cancer chemotherapy;Coates;Eur J Cancer Clin Oncol,1983
3. The impact of cytotoxic chemotherapy—perspectives from patients, specialists and nurses;Cooper;Eur J Cancer,1992
4. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study;Goedhals;Ann Oncol,1998
5. Nausea, vomiting, and retching: complex problems in palliative care;Rhodes;CA Cancer J Clin,2001
Cited by
166 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献